BioLineRx receives notification of allowance from USPTO for motixafortide

BioLineRx announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office, or USPTO, for a patent, titled, “COMPOSITION OF BL-8040,” which covers the composition of motixafortide, or APHEXDA/BL-8040. The patent strengthens BioLineRx’s robust intellectual property estate and extends its patent protection on motixafortide in the U.S. through December 2041. In addition to a broad range of U.S. and international patents covering various aspects of motixafortide, including composition of matter, methods of synthesis, methods of use and combinations, BioLineRx was granted seven years of Orphan Drug market exclusivity beginning on September 8, 2023, the day APHEXDA was approved by the FDA, in combination with G-CSF, for use by multiple myeloma patients undergoing autologous stem cell transplantation. Additionally, motixafortide was granted five years of data exclusivity across all indications as a New Chemical Entity, or NCE. The NCE exclusivity also commenced on September 8, 2023.